SCHEMBL908781

SCHEMBL908781

O=c1[nH]cccc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 1/20 0.47
DAO P14920 2/20 0.46
AURKA O14965 1/20 0.46
AURKB Q96GD4 1/20 0.46
INCENP Q9NQS7 1/20 0.46
PARP1 P09874 2/20 0.44
MCL1 Q07820 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
CES1 P23141 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5263184 0.89 NAPRT (0.47) KDM4ESMN1; SMN2HSD17B10DAOAURKA
SCHEMBL29700994 0.82 NOTUM (0.45) KDM4ESMN1; SMN2HSD17B10DAOAURKA
SCHEMBL6984148 0.77 DAO (0.52) KDM4EDAOAURKAAURKBINCENP
SCHEMBL25330569 0.75 DAO (0.41) KDM4ESMN1; SMN2HSD17B10DAOAURKA
SCHEMBL25799818 0.74 DAO (0.43) KDM4EDAOAURKAAURKBINCENP
SCHEMBL24879524 0.74 DAO (0.48) KDM4EHSD17B10DAOAURKAAURKB
SCHEMBL19325274 0.74 DAO (0.43) KDM4EDAOAURKAAURKBINCENP
SCHEMBL1536662 0.74 KDM4E (0.57) KDM4ESMN1; SMN2HSD17B10PARP1MEN1
SCHEMBL16445619 0.73 KDM4E (0.39) KDM4ESMN1; SMN2HSD17B10PARP1CES1
SCHEMBL19687778 0.72 JAK2 (0.56) KDM4ESMN1; SMN2HSD17B10PARP1CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577239-B2 Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds PI INDUSTRIES LTD. (IN) 2026-03-17 US claimed
EP-4558500-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-05-28 EP claimed
CN-115052875-B 4- (4, 5-Dihydroisoxazol-3-yl) thiazol-2-yl) piperidine-thioimine or sulphoxide-imine derivatives and related compounds as fungicides for crop protection PI工业有限公司 2024-07-12 CN claimed
WO-2024017977-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-01-25 WO claimed
US-20230012782-A1 NOVEL SULFILIMINES OR SULFOXIMINES CONTAINING FUNGICIDAL HETEROCYCLIC COMPOUNDS PI INDUSTRIES LTD. (IN) 2023-01-19 US claimed
EP-4058450-A2 4-(4-(4,5-DIHYDROISOXAZOL-3-YL)THIAZOL-2-YL) PIPERIDINE SULFILIMINE AND SULFOXIMINE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES FOR CROP PROTECTION PI Industries Ltd. (IN) 2022-09-21 EP claimed
CN-115052875-A 4- (4- (4, 5-dihydroisoxazol-3-yl) thiazol-2-yl) piperidinethimine or sulfoximine derivatives as fungicides for crop protection and related compounds PI工业有限公司 2022-09-13 CN claimed
WO-2018193387-A1 HETEROCYCLIC COMPOUNDS WITH MICROBIOCIDAL PROPERTIES PI INDUSTRIES LTD. (IN) 2018-10-25 WO claimed
EP-3057586-A1 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2016-08-24 EP claimed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 WO claimed
EP-1869045-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2007-12-26 EP claimed
WO-2006107254-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2006-10-12 WO claimed
EP-0806455-B1 Methine and azamethine dyes derived from trifluoromethylpyridones DYSTAR TEXTILFARBEN GMBH & CO (DE) 2002-08-28 EP claimed
US-5892046-A DYES FOR PRINTING SYNTHETIC MATTERIAL BASF AKTIENGESELLSCHAFT (DE) 1999-04-06 US claimed
EP-0806455-A2 Methine and azamethine dyes derived from trifluoromethylpyridones BASF AKTIENGESELLSCHAFT (DE) 1997-11-12 EP claimed
CN-86106734-A ARYL PYRIDONES 1987-04-01 CN claimed
EP-4745129-A2 COMPOUND HAVING CYCLIC STRUCTURE Daiichi Sankyo Company, Limited (JP) 2026-05-20 EP disclosed
EP-3682881-B1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO CO LTD (JP) 2026-04-01 EP disclosed
US-4546191-A Trifluoromethyl-2-pyridinone or pyridinthione compounds and process for the preparation of the same ISHIHARA SANGYO KAISHA LTD. (JP) 1985-10-08 US disclosed
US-4546191-A Trifluoromethyl-2-pyridinone or pyridinthione compounds and process for the preparation of the same ISHIHARA SANGYO KAISHA LTD. (JP) 1985-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230012782-A1 NOVEL SULFILIMINES OR SULFOXIMINES CONTAINING FUNGICIDAL HETEROCYCLIC COMPOUNDS SULT1E1, SULT1A1, STS KDM4E 1308/4885SMN1; SMN2 2118/4885HSD17B10 1689/4885
US-12577239-B2 Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds SULT1E1, CBR1, SULT1A1 KDM4E 1803/4885SMN1; SMN2 1833/4885HSD17B10 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.